Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
Pharmaceutics · 04.01.2023 · 15 (1) · 182
DOI: 10.3390/pharmaceutics15010182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.01.2023. Verfasst von Lien Thi Ngo und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Information and Communications Technology Promotion, Korea Environmental Industry and Technology Institute, Institute of Information Communications Technology Planning Evaluation (IITP).
Abstract (Originalsprache)
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegoprazan is likely to be administered in combination with various drugs. Therefore, the investigation of drug–drug interactions (DDI) between tegoprazan and CYP3A4 perpetrators is imperative. In the present study, we first aimed to develop a physiologically based pharmacokinetic (PK) model for tegoprazan and its major metabolite, M1, using PK-Sim®. This model was applied to predict the DDI between tegoprazan and CYP3A4 perpetrators. Clarithromycin, a potent inhibitor of CYP3A4, and rifampicin, a strong inducer of CYP3A4, were selected as case studies. Our results show that clarithromycin significantly increased the exposure of tegoprazan. The area under the concentration–time curve (AUC) and Cmax of tegoprazan in the steady state increased up to 4.54- and 2.05-fold, respectively, when tegoprazan (50 mg, twice daily) was coadministered with clarithromycin (500 mg, three times daily). Rifampicin significantly reduced the exposure of tegoprazan. The AUC and Cmax of tegoprazan were reduced by 5.71- and 3.51-fold when tegoprazan was coadministered with rifampicin (600 mg, once daily). Due to the high DDI potential, the comedication of tegoprazan with CYP3A4 perpetrators should be controlled. The dosage adjustment for each individual is suggested.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea.
ORCID-Profile: Lien Thi Ngo, Jaeyeon Lee, Hwi-Yeol Yun, Jung-Woo Chae
Förderung
- Institute for Information and Communications Technology Promotion
- Korea Environmental Industry and Technology Institute
- Institute of Information Communications Technology Planning Evaluation (IITP)
- Korean government (MSIT)
- Korea Ministry of Environment (MOE)
- National Research Foundation of Korea (NRF)
Zitieren
APA
Ngo, L. T., Lee, J., Yun, H. Y., & Chae, J. W. (2023). Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators. Pharmaceutics, 15(1), 182. https://doi.org/10.3390/pharmaceutics15010182
Vancouver
Ngo LT, Lee J, Yun HY, Chae JW. Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators. Pharmaceutics. 2023;15(1):182. doi:10.3390/pharmaceutics15010182
BibTeX
@article{Ngo2023,
author = {Ngo, Lien Thi and Lee, Jaeyeon and Yun, Hwi-Yeol and Chae, Jung-Woo},
title = {Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {1},
pages = {182},
doi = {10.3390/pharmaceutics15010182}
}
EUVIMED